Abstract: Embodiments are related to ionic liquids and more specifically to ionic liquids used in electrochemical metal-air cells in which the ionic liquid includes sulfonate ions as the anion.

Abstract: Various systems generating nitric oxide are disclosed herein. According to one embodiment, the system includes a first gas source providing nitrogen dioxide mixed in air or oxygen, and a second gas source supplying compressed air and/or compressed oxygen. The system also includes a ventilator coupled to the first and second gas sources, wherein the ventilator is resistant to nitrogen dioxide. The ventilator regulates gas flow and allows for the adjustment of nitrogen dioxide concentration in the gas flow. The system further includes one or more conversion devices operably coupled to the ventilator where the conversion devices convert nitrogen dioxide into nitric oxide. A patient interface delivers nitric oxide to the patient and is operably coupled to the conversion devices. The system allows oxygen and nitric oxide levels to be varied independently.

Abstract: An ambulatory or stationary device for delivery of a therapeutic amount of nitric oxide to an individual's lungs.

Abstract: A computer-based method for calibrating a solenoid-controlled excess flow control valve that couples a first hydraulic circuit to a second hydraulic circuit is provided. The method includes determining a start-of-flow current at which hydraulic fluid begins to flow, closing the valve, sending an actuator command to the second hydraulic circuit, determining a first flow through the hydraulic actuator, opening the valve by setting the solenoid current to a calibration-flow current, sending the actuator command to the second hydraulic circuit, determining a second flow through the hydraulic actuator, calculating a flow difference, determining a calibration-flow valve command associated with the flow difference, determining a maximum-flow current based on the start-of-flow current, the calibration flow current, and the calibration-flow valve command, and creating a valve calibration table based on the start-of-flow current, the maximum-flow current and a valve response table.

Abstract: A method of delivering nitric oxide can include mixing a first gas including oxygen and a second gas including a nitric oxide-releasing agent within a receptacle to form a gas mixture, where the receptacle includes an inlet, an outlet and a reducing agent, contacting the nitric oxide-releasing agent in the gas mixture with the reducing agent to generate nitric oxide, and delivering the gas mixture including nitric oxide from the receptacle to a mammal.

Abstract: A system for the delivery of nitric oxide can include a first platform including a first source of nitric oxide, a second platform including a second source of a nitric oxide, a delivery line coupled to the first platform and the second platform, and a controller configured to operate the first platform and the second platform simultaneously. A method of delivering nitric oxide can include communicating a first gas including nitric oxide through a first platform to a delivery line, communicating a second gas including nitric oxide through a second platform to the delivery line, and delivering the first gas and the second gas to a mammal via a delivery line.

Abstract: A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

Abstract: In one aspect, a system for delivering nitric oxide to a patient can include a first gas source including nitrogen dioxide mixed in air or oxygen, a second gas source supplying compressed air, a ventilator coupled to the first and second gas sources, where the ventilator can be resistant to nitrogen dioxide, and where the ventilator provides a gas flow having a proper amount of nitrogen dioxide, one or more conversion devices operably coupled to the ventilator, where the conversion devices covert nitrogen dioxide into nitric oxide, and a patient interface operably coupled to the conversion devices, where the patient interface delivers nitric oxide to the patient.

Abstract: Various systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.

Abstract: An ambulatory or stationary device for delivery of a therapeutic amount of nitric oxide to an individual's lungs.

Abstract: Various systems and devices for generating nitric oxide are disclosed herein. According to one embodiment, the device includes a body having an inlet, an outlet, and a porous solid matrix positioned with the body. The porous solid matrix is coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the solid matrix to convert nitrogen dioxide in the gas flow into nitric oxide. The porous solid matrix allows the device to be used in any orientation. Additionally, the porous solid matrix provides a rigid structure suitable to withstand vibrations and abuse without compromising device functionality.

Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.

Abstract: Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.

Abstract: A hydraulic control system is disclosed. The hydraulic control system may have a pump configured to pressurize a fluid, an actuator, a position sensor associated with the actuator and configured to generate a first signal indicative of a position of the actuator, and a circuit fluidly connecting the pump to the actuator. The hydraulic control system may also have a valve associated with the circuit and configured to move from a first position, at which fluid relief from the circuit is inhibited, toward a second position, at which fluid is relieved from the circuit through the valve, when a pressure of fluid within the circuit exceeds a threshold setting of the valve. The hydraulic control system may additionally have a controller in communication with the position sensor and the valve. The controller may be configured to selectively cause adjust the threshold setting of the valve based on the first signal.

Abstract: Methods of preparing hetero ionic complexes, and ionic liquids from bisulfate salts of heteroatomic compounds using dialkylcarbonates as a primary quaternizing reactant are disclosed. Also disclosed are methods of making electrochemical cells comprising the ionic liquids, and an electrochemical cell comprising an alkaline electrolyte and a hetero ionic complex additive.

Abstract: Embodiments are related to ionic liquids and more specifically to ionic liquids used in electrochemical metal-air cells in which the ionic liquid includes sulfonate ions as the anion.

Abstract: Embodiments of the invention are related to anion exchange membranes used in electrochemical metal-air cells in which the membranes function as the electrolyte material, or are used in conjunction with electrolytes such as ionic liquid electrolytes.

Abstract: Methods of preparing sulfate salts of heteroatomic compounds using dialkyl sulfates as a primary reactant are disclosed. Also disclosed are methods of making ionic liquids from the sulfate salts of the heteroatomic compound, and electrochemical cells comprising the ionic liquids.

Abstract: A pharmaceutical product can include a pressure vessel containing a pressurized gas including at least about 1% nitric oxide.

Abstract: Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.